AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
AptarGroup, Inc.
Video analysis: ATR
All videosNo video analysis for this stock yet. Request one from our team.
News: ATR
AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen, with no serious device-related adverse events reported Findings reinforce results from the STAR-T trial and are expected to form a core component of additional real-world evidence planned for a new U.S. FDA De Novo submission for DrugSorb-ATR® Recent FDA Pre-Submission meetings provided constructive feedback on potential U.S. regulatory pathways for DrugSorb-ATR for separate applications for ticagrelor and direct oral anticoagulant removal in urgent cardiac surgery PRINCETON, N.J., Sept. 2, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced an independent new patient-level matched analysis of real-world data demonstrating that intraoperative use of CytoSorb was associated with a significant reduction in severe perioperative bleeding among patients undergoing urgent coronary artery bypass grafting (CABG) surgery on the blood thinner, ticagrelor (Brilinta®/Brilique®, AstraZeneca).
Callan Family Office LLC Makes New Investment in AptarGroup, Inc. $ATR
Callan Family Office LLC acquired a new stake in AptarGroup, Inc. (NYSE: ATR) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,429 shares of the industrial products company's stock, valued at approximately $1,181,000. A number of other
Deutsche Bank AG Invests $14.90 Million in AptarGroup, Inc. $ATR
Deutsche Bank AG bought a new stake in AptarGroup, Inc. (NYSE: ATR) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 119,035 shares of the industrial products company's stock, valued at approximately $14,903,000. Deutsche Bank AG owned approximately 0.19% of
Aurora Investment Counsel Acquires New Stake in AptarGroup, Inc. $ATR
Aurora Investment Counsel acquired a new stake in shares of AptarGroup, Inc. (NYSE: ATR) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 11,785 shares of the industrial products company's stock, valued at approximately $1,475,000. Other hedge funds have
Dividend Champion, Contender, And Challenger Highlights: Week August 16
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress including FDA clearance of its Investigational New Drug (IND) application for ATR 1072 and continued achievements under its collaboration with Bristol Myers Squibb (BMS). "Our team continues to execute well, achieving FDA clearance of our IND for ATR 1072 and launching Corventis — Atrium's first Phase 1/2 trial and the first clinical study to evaluate a potential disease-modifying treatment for people living with PRKAG2 syndrome," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics.
AptarGroup, Inc. $ATR Shares Acquired by Bank of America Corp DE
Bank of America Corp DE boosted its position in AptarGroup, Inc. (NYSE: ATR) by 7.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 485,718 shares of the industrial products company's stock after buying an additional 32,420 shares during the
Similar companies
-
Stevanato Group S.p.A.
STVN
·
New York Stock Exchange
Compare
-
Henry Schein, Inc.
HSIC
·
NASDAQ
Compare
-
Avantor, Inc.
AVTR
·
New York Stock Exchange
Compare
-
Halozyme Therapeutics, Inc.
HALO
·
NASDAQ
Compare
-
Grifols, S.A.
GRFS
·
NASDAQ
Compare
-
Molina Healthcare, Inc.
MOH
·
New York Stock Exchange
Compare